期刊文献+

沉默PKM2对乳腺癌他莫昔芬耐药MCF-7细胞系侵袭及迁移的影响

Influence of PKM2 silencing on invasion and migration in tamoxifen-resistant breast cancer cell line MCF-7
下载PDF
导出
摘要 目的探讨PKM2下调对乳腺癌他莫昔芬(TAM)耐药MCF-7细胞系侵袭、迁移的影响。方法以浓度梯度法诱导获得乳腺癌他莫昔芬耐药细胞系(MCF-7R);细胞增殖与凋亡试剂盒(CCK-8)检测细胞增殖能力;Western blot检测细胞PKM2的表达;将表达针对PKM2的shRNA慢病毒干扰载体感染耐药细胞系,RT-q PCR、Western blot验证干扰效果,分别用Transwell侵袭实验、划痕实验检测细胞侵袭、迁移能力。结果与MCF-7细胞相比,MCF-7R细胞对他莫昔芬的抵抗能力显著增强(P<0.01),PKM2的表达水平明显升高(P<0.01)。稳定干扰PKM2的耐药细胞中PKM2的mRNA和蛋白水平较对照组均明显下降(P<0.01),PKM2干扰后可明显抑制MCF-7R细胞的侵袭、迁移能力(P<0.01)。结论 MCF-7R细胞中PKM2表达明显高于MCF-7细胞,沉默PKM2可以抑制MCF-7R细胞的侵袭和迁移能力。 Objective To investigate the effect of PKM2 down-regulation on invasion and migration in tamoxifenresistant breast cancer cell line MCF-7. Methods The tamoxifen-resistant breast cancer cell line( MCF-7 R)was established by increasing tamoxifen concentration in a stepwise manner. CCK-8 was used to measure the proliferation of cells. The protein expression of PKM2 was determined by Western blot. shRNA for PKM2 gene lentiviral interference vectors were infected into MCF-7 R cells,the effect of interference was determined by RT-q PCR and Western blot. Cell invasion and migration abilities were measured by Transwell and wound-healing assays.Results The capability of tamoxifen resistance in MCF-7 R cells was dramatically enhanced compared to that in MCF-7 cells( P〈 0. 01). Protein level of PKM2 was markedly increased in MCF-7 R cells( P〈 0. 01). The mRNA and protein levels of PKM2 declined obviously in PKM2-silented MCF-7R cells( P〈 0. 01). Knockdown of PKM2 significantly inhibit the invasion and migration of MCF-7 R cells( P〈 0. 01). Conclusions The expressionof PKM2 is apparently higher in MCF-7R than that in MCF-7 cells. Moreover,knockdown of PKM2 can inhibit the migration and invasion of MCF-7R cells.
出处 《基础医学与临床》 CSCD 2016年第12期1641-1645,共5页 Basic and Clinical Medicine
基金 国家自然科学基金(81272544)
关键词 乳腺肿瘤 他莫昔芬 M2-型丙酮酸激酶 侵袭 迁移 breast cancer tamoxifen pyruvate kinase M2 invasion migration
  • 相关文献

参考文献1

二级参考文献22

  • 1Dittmer J, Leyh B. The impact of tumor stroma on drug response in breast cancer[J]. Sernin Cancer Biol, 2015(31):3-15.
  • 2Knutson TP, Lange CA. Tracking progesterone receptor-mediated actions in breast cancer[I]. Pharmacol Ther, 2014, 142(1):114-125.
  • 3Li Z, Yang P, Li Z. The multifaceted regulation and functions of PKM2 in tumor progression[J]. Biochim Biophys Acta, 2014, 1846(2):285-296.
  • 4Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer[J]. Trends Biochem Sci, 2012, 37(8):309-316.
  • 5Demaria M, Poli V. PKM2, STAT3 and HIF-lalpha: the Warburg's vicious circte[J].JAKSTA T, 2012, 1 (3): 194-196.
  • 6Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression[J]. Trends Endocrinol Metab, 2012, 23(11 ):560-566.
  • 7Wang F, Yang Y. Inhibition of PKM2 sensitizes triple-negative breast cancer cells to doxorubicin[J]. Biochem Biophys Res Cornmun, 2014,454(3):465-470.
  • 8Jiang Y, Wang Y, Wang T, et al. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells[J]. Nat Commun, 2014(5):5566.
  • 9Yang W, Xia Y, Ji H, eta/. Nuclear PKM2 regulates 13-catenin transactivation upon EGFR activation[J]. Nature, 2011, 478(7375):118-122.
  • 10Wu H, Li Z, Yang P, et al. PKM2 depletion induces the compensation of glutarninolysis through 13-catenin/ c-Myc pathway in tumor cells[J]. Cell Signal, 2014, 26(11 ):2397-2405.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部